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Abstract
Background: Catatonia is a potentially life-threatening but treatable neuropsychiatric condition. Although
considered more common in low income countries, data is particularly sparse in these settings. In this study we
explore the symptomatology, treatment, and short-term outcome of catatonia in Ethiopia, a low income country.
Methods: The study was a prospective evaluation of patients admitted with a DSM-IV diagnosis of catatonia.
Diagnosis of Catatonia and its severity were further assessed with the Bush-Francis Catatonia Rating Scale (BFCRS).
Results: Twenty participants, 5 male and 15 female, were included in the study: 15 patients (75 %) had underlying
mood disorders, 4 patients (20 %) had schizophrenia and 1 patient (5 %) had general medical condition. The most
common catatonic symptoms, occurring in over two-thirds of participants, were mutism, negativism, staring and
immobility (stupor). Eighteen (90 %) of the twenty patients were on multiple medications. Antipsychotics were the
most commonly prescribed medications. ECT was required in seven patients (35.0 %). Dehydration, requiring IV
rehydration, and infections were the most important complications ascribed to the catatonia. These occurred in
seven patients (25 %). Almost all patients (n = 19/20) were discharged with significant improvement.
Conclusion: This study supports the growing consensus that catatonia is most often associated with mood
disorders. Overall prognosis appears very good although the occurrence of life-threatening complications
underlines the serious nature of catatonia. This has implication for “task-shifted” service scale up plans, which
aim to improve treatment coverage by training non-specialist health workers to provide mental health care in
low income countries. Further larger scale studies are required to clarify the nature and management, as well as,
service requirements for catatonia.
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Background
Catatonia is a neuropsychiatric syndrome characterized
by motor, cognitive, affective, and sometimes autonomic
disturbances. More than 40 signs of catatonia have been
described in the literature [1–3] although stupor, mut-
ism, negativism, and posturing are some of the most
commonly recognized signs [4, 5]. Diverse causes of
catatonia, ranging from primary psychiatric disorders to
idiopathic causes have been described [6]. In addition to
the interest in the behavioural symptoms, neurobio-
logical basis, epidemiology and management, [7–10],
several studies have reported that anxiety is the most
common subjective feeling reported by catatonic pa-
tients upon recovery [7–9, 11–13].
Since Karl Kahlbaum’s original description in his his-
torical monograph entitled catatonia or tension insanity
[14, 15] over a century ago, catatonia has been a subject
of constant fascination and controversy. While some
consider it to be a potentially distinct syndrome deserv-
ing its own nosological status [3, 16, 17], others are un-
sure [18, 19]. Even though catatonia has been strongly
associated with schizophrenia due to the enduring influ-
ence of Emil Kraeplin and Eugene Bleuler [20], many pa-
tients with catatonia have mood disorders, while a
sizeable proportion of patients with schizophrenia have
catatonic features.[3, 13, 21–25]. Related to the historical
views is the assumption that that there is a decline in the
prevalence of catatonia in high-income countries [26, 27],
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while it remains relatively common in low income coun-
tries [3, 28]. For example, the International Pilot Study of
Schizophrenia, a cross-country cohort study of schizo-
phrenia involving both high and low income countries,
has described catatonia to be more common in low in-
come countries [29]. However, systematic studies on the
subject are limited, particularly in low income countries.
The possible contribution of genetics, socio-cultural, en-
vironmental and public health factors as well as change in
clinical practice to the difference in prevalence of catato-
nia between the high income and low income countries is
not settled [29, 30]. There are also uncertainties around
the best treatment practices even if current treatment rec-
ommendations favor the use of benzodiazepines with
electro-convulsive therapy (ECT) reserved for patients
who fail to respond to adequate treatment with more con-
servative approaches [18]. For example, when catatonic
symptoms occur in the context of chronic schizophrenia,
response to treatment with benzodiazepines has been less
favorable [31, 32]. The role of antipsychotics is still con-
troversial. The common recommendation is to avoid anti-
psychotics at least during the early phases of treatment to
avoid antipsychotic-associated neuroleptic malignant syn-
drome (NMS), which has been believed to occur in up to
10 % of patients with catatonia treated with antipsychotics
[33–35]. The prognosis of catatonia is variable, ranging
from good recovery to acutely rapid progression to death
(often complicated by renal failure). Instituting appropri-
ate treatment promptly may prevent complications and
improves outcome [36–38]. Despite the recent revival of
interest in the study of catatonia [16], contributions to the
field from low income countries has been scarce and vir-
tually non-existent in sub-Saharan Africa. The primary
purpose of this study was to describe the profile of symp-
toms occurring in catatonia, and to evaluate the treatment
and outcome of catatonia in a low income country. It was
also hoped that the study would help to clarify effective
management choices in low income countries.
Methods
Study design and setting
The study design was a facility based prospective obser-
vational study and was conducted at Amanuel hospital.
Amanuel is the only psychiatric hospital in Ethiopia, al-
though psychiatric care is provided in all the main cities
of the country as part of integrated care provision. Pa-
tients from across the country use Amanuel hospital,
but as would be expected, most users come from Addis
Ababa or the surrounding areas [39]. The hospital has
280 beds and many of the psychiatrists of the country
work in the hospital. The hospital service is organized in
case teams based on the main diagnostic categories. The
treatments available for psychosis are primarily first
generation antipsychotics, with two second generation
antipsychotics (olanzapine and resperidone), which are
not always available. The main benzodiazepine consist-
ently available is diazepam. Lorazepam is not available in
the hospital or the country. The hospital runs the only
electro-convulsive therapy (ECT) service in the country.
Admitted patients, particularly those with more severe ill-
ness, are required to have their families with them.
Participants
The study participants were recruited between June and
September 2011 from the inpatient services of Amanuel
hospital. Cases confirmed to have catatonia syndrome by
the treating psychiatrists according to the Diagnostic
and Statistical Manual of Mental Disorders, 4th revision
(DSM-IV) [4] were referred to the research team for fur-
ther assessment. Treatment was initiated and managed
by the treating psychiatrist.
Inclusion criteria
Patients, age 15 years and above, admitted to the hos-
pital with a diagnosis of catatonia syndrome during the
study period and having two or more items positive
from the BFCRS screening criteria were recruited into
the study.
Sample size
The study was exploratory and hypothesis generating.
Therefore, cases admitted to the hospital consecutively
during the study period constituted the study sample
and no formal sample size estimation was carried out.
Measures
Baseline assessment
A simple historical, clinical and socio-demographic in-
ventory developed for this study and BFCRS were ad-
ministered at baseline. The inventory allowed extraction
of information from clinical records and recording of
additional information obtained from direct interview.
Information of interest included clinical presentation at
the index admission, past psychiatric history and family
history of similar illness. Presence and severity of catato-
nia was assessed at baseline using the BFCRS. The
BFCRS has 23 items and is a widely used scale [40] with
established reliability and validity [1]. The BFCRS serves
both to screen for catatonia and to estimate its severity.
The first 14 items of the scale serve as screening tool.
Positive response to two of these screening items con-
firms the occurrence of catatonia. These 14 items and a
set of nine additional items are used to rate for the se-
verity of the catatonia.
Follow-up assessment
The BFCRS was administered at discharge. All treat-
ments (including doses of drugs) were recorded using a
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separate treatment recording form. A semi-structured
questionnaire was also administered to five fully recov-
ered patients to explore retrospectively subjective feel-
ings during the catatonic state.
Raters
A senior resident administered all the questionnaires.
Data analysis
Data were entered into version 20 of the Statistical Pack-
ages for Social Sciences (SPSS). Data analysis was also
carried out in SPSS. Analyses focused on description of
baseline demographic and clinical profiles, including the
profile of catatonic symptoms. Simple comparative ana-
lyses were conducted focused on comparing the preva-
lence of the different catatonic symptoms in patients
with underlying diagnosis of schizophrenia and mood
disorders. Outcome data obtained prospectively was also
handled through simple descriptive analytic methods.
The study was approved by the Scientific Committee of
the Department of Psychiatry, Addis Ababa University,
and the Ethics Committee of Amanuel hospital. Consent
process relied on obtaining written permission from
guardians of patients who were accompanying patients in
the wards. Permission was obtained from guardians after
adequate information was provided by the study team. All
seriously ill inpatients are required to be accompanied by
their relatives while they are in hospital.
Results
Baseline demographic and clinical characteristics
A total of 20 participants were recruited during the
study period. Fifteen participants were admitted for their
first episode of illness, and 17 were treatment naïve and
presented to seek care for the first time. The mean age
(SD) of participants was 24.0 (7.8) years, ranging from
15 to 45. Most of the participants (n = 15; 75 %) were fe-
males and from rural parts of the country (n = 12; 60 %).
Seventeen (85 %) were single and either students or un-
employed prior to the onset of their illness (Details are
provided in Table 1). Fifteen participants (75 %) had a
diagnosis of mood disorder with catatonic features; all of
these had depressive disorder except one who was ad-
mitted with a depressive phase of bipolar I disorder.
Four participants (20 %) had a diagnosis of catatonic
schizophrenia and one participant (5 %) a diagnosis of
catatonia due to general medical condition (GMC), the
GMC being Human Immunodeficiency Virus infection/
Acquired Immunodeficiency Syndrome (HIV/AIDS). Par-
ticipants with schizophrenia were older, with a mean age
(SD) of 29.8 (10.5) years compared to those with a diagno-
sis of underlying mood disorders (Mean (SD) =23.6 (6.6)
years. Comorbid substance use was elicited only in one
patient who was admitted with a diagnosis of schizophre-
nia. Further details are presented in Table 1.
Catatonic symptoms
At admission, the mean (SD) BFCRS score for the whole
sample was 15.9 (5.8). The participants admitted with
GMC had the highest score (26.0). The mean (SD) score
for those with schizophrenia was 19 (6.1) while for those
with mood disorders was 14.3 (5.0). Figure 1 presents
the symptom profile of the 20 participants based on the
23 items of the BFCRS. All items were rated except two,
echophenomena and perseveration. However, only seven
of the 23 items were found in 50 % or more of the par-
ticipants: mutism (95 %), staring (75 %), negativism
(70 %), immobility (stupor) (70 %), withdrawal (65 %),
waxy flexibility (50 %) and posturing (50 %). In addition
to the items that were completely absent (echopheno-
mena and perseveration), verbigeration, automatic
obedience and comabtiveness were the lowest rated oc-
curring in only 5 % of the patients. Exploratory compari-
son focusing on schizophrenia and mood disorders
showed that participants with schizophrenia have more
catatonic symptoms (Figure 2). The main exception is im-
mobility (stupor), which was higher among those with
mood disorders. Slight increase was also observed in ste-
reotyped behavior, grimacing and verbigeration among par-
ticipants with mood disorders. All participants with
schizophrenia (n = 4) had mutism, staring and negativisim.
The patient with catatonia due to GMC had 10 of the 23
symptoms (excitement, mutism, posturing, stereotypy,
mannerism, rigidity, negativism, withdrawal, impulsivity
and gegenhalten). The mean (SD) duration of catatonic
symptoms among patients with schizophrenia was 295
(326) days while the comparable figures for those with
mood disorders were 38.6 (37.3) days. The patient with
GMC had the symptoms for 21 days prior to admission.
Overall, possible factors that were considered relevant
triggers for the catatonia were elicited in five patients
with major depressive disorder and the patient with
GMC. In those with major depressive disorders, three
patients had academic problems while two were re-
turnees from the Middle East.
Treatment and outcomes
Four classes of treatment were used (Table 2). Antipsy-
chotics were the most commonly used (n = 19/20; 95 %)
followed by benzodiazepines (n = 15/20; 70 %) and antide-
pressants (n = 9; 60 %). ECT was also used in seven cases
(35 %). Where benzodiazepines were used, they were initi-
ated before the administration of antipsychotic medications.
Among the antipsychotics, olanzapine was used in 11/19
cases in doses ranging from 5 mg to 15 mg. Haloperidol
was used in seven cases in doses ranging from 1.5 mg to
5 mg. Chlorpromazine (200 mg) was also used in one case
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with mood disorder. Electroconvulsive therapy was used
for three cases with schizophrenia, three cases with mood
disorders and in the only case of GMC. Diazepam in doses
of 5–20 mg, bromazepam (3–6 mg) and clonazepam
(0.5 mg) were the benzodiazepines used. Amitriptyline and
imipramine were used in two cases each for patients with
mood disorders in doses ranging from 25 mg to 75 mg. Flu-
oxetine was used in the remaining five cases in doses of
20–40 mg. Eighteen of the 20 patients were treated with
two or more medications from different groups or ECT.
Seven participants had complications during their
hospitalization. Five of the cases had dehydration neces-
sitating intravenous resuscitation. One case had hypo-
static pneumonia and another urinary tract infection.
None of the patients developed symptoms suggestive of
neuroleptic malignant syndrome.
All participants were discharged with good improvement
except one case that was discharged against medical advice
as the family decided to take her home (Table 2). The
mean (SD) discharge score of BFCRS for those with


























Mood Disorders 15 75
Catatonia due to General Medical Condition 1 5
Precipitating factors identified – 7 35
Substance use history – 1 5
Past history of catatonia – 2 10
First service contact – 17 85
Mean SD
Duration of catatonic symptoms before admission in days–Mean, SD
Schizophrenia 295 326
Mood Disorders 38.6 37.3
GMC 21 –
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schizophrenia was 3.8 (1.9). The comparable mean (SD)
score for those with mood disorders was 0.9 (1.7). While
only one case with schizophrenia had a score of zero, 10 of
those with mood disorders scored zero at discharge. ECT
was particularly effective with five of the seven cases
treated with ECT scoring zero on the BFCRS. The overall
mean (SD) duration of hospital stay was 34.5 (26.3),
longest for schizophrenia (mean (SD) =40.7 (15.8) days)
and shortest for the cases with mood disorders (mean
(SD) =33.5 (30.3) days). Patients who received benzodi-
azepines had the shortest duration of hospitalization
while those treated with ECT had the longest.
Two patients who were diagnosed with Major Depres-
sive Disorder (MDD) had recurrent catatonia. One of the
patients with recurrent catatonia was admitted 3 years ago
with a diagnosis of MDD with catatonic features that
resolved after treatment with ECT. The second patient
had four episodes of probable catatonia over a period
of 13 years. Each episode lasted 10–15 days on average
and they resolved without any treatment. This patient
responded to treatment with benzodiazepines while a
full course of ECT was necessitated in the first case.
It was possible to obtain subjective experience from
four participants with underlying depressive disorder
and one patient admitted with a diagnosis of catatonia
due to GMC. All reported feeling anxious and the four
patients who had immobility did not recall being unable
to move their body.
Discussion
This is the first report of catatonia syndrome from
Ethiopia and one of the very few from any low income
country. This study supports the existing literature that:
(1) catatonia may be most commonly associated with
mood disorders; (2) catatonia responds relatively well to
treatment; (3) catatonia could threaten life considering
the relatively high number of cases with serious com-
plications. Given the relative paucity of systematic data
on catatonia, our study may be an important addition
to the literature.
Comparison with the broader literature
The results of our study for the most part concur well
with results of studies reported in the wider literature
[16, 17, 19, 41]. A study summarizing data from over
1000 patients indicated that mood disorders were com-
mon causes of catatonia [3, 42]. The trend of the pro-
portions of underlying conditions (mood disorder >
schizophrenia > GMC) in our sample is consistent with
other studies [20, 43, 44]. However, unlike our study
where only one participant with mood disorder had bi-
polar disorder, many catatonic patients in some of these
older studies had bipolar disorder [1, 41]. This discrep-
ancy may partly be explainable by the fact that most of
our participants with mood disorders (13 of the 15)
were first episode cases. This is consistent with the fact
that bipolar I disorder may often start with depression
[45]. The broader demographic characteristics of our
sample, specifically the mean age of participants, and
the male to female ratio are consistent with other re-
ports [24, 25, 31, 41, 46, 47].
The mean total score on the BFCRS at the initial as-
sessment was almost equal to the score of 16.8 (SD 6.6)
found by Bush and colleagues among 28 patients with
catatonia [48]. The most common catatonic symptoms
identified in our patients were also similar to the find-
ings of several well designed studies [1, 13, 24, 30, 48].
The good treatment outcome observed is congruent
with the conclusion of experts that prognosis is excel-
lent provided that there is prompt detection and appro-
priate management. However, the very high rate of
polypharmacy and lack of uniformity in management
shows the need for the application of evidence based
treatment protocol [36–38]. The high rate of response
in patients treated with ECT is consistent with the evi-
dence base. The longer duration of hospitalization ob-
served in patients who ultimately required treatment
with ECT is because ECT is given usually as treatment
of last resort [36]. The observed higher prevalence of
potentially life-threatening complications indicates the
level of risk associated with catatonia and the need for
Table 2 Treatment and outcome characteristics of patients with catatonia syndrome
Underlying diagnostic group
Schizophrenia Mood Disorders General Medical Condition
Treatment No Percent No Percent No. Percent Total (%)
Benzodiazepines 1 25.0 12 80.0 1 100.0 14 (70)
Antidepressants 0 0.0 9 60.0 0 0.0 9 (45)
Antipsychotics 4 100.0 13 86.7 1 100.0 18 (90)
Electroconvulsive therapy 2 50.0 3 20.0 1 100.0 6 (30)
Outcomes mean SD mean SD mean SD Overall mean (SD)
Length of hospital stay 40.8 15.9 33.5 30.3 39 – 34.5 (26.3)
Bush-Francis Severity scores 3.5 2.4 2.8 6.9 0 – 2.7 (5.9)
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Fig. 1 Proportion of patients with specific catatonic features from the full scale of the Bush-Francis scale
Fig. 2 Catatonic features from the 14 screening items of the Bush-Francis scale comparing those with underlying diagnosis of schizophrenia and
mood disorders
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robust interventions in this patient population. The
current plan for scaling up mental healthcare in low
and middle income countries, exemplified by the men-
tal health gap action program proposed by the World
Health Organization [49] should take into account the
needs of patients with catatonia, particularly given the
relatively common occurrence of catatonia and poten-
tial risks of untreated catatonia. Training of primary
care workers on the manifestations and treatment of
catatonia and ensuring benzodiazepines are available at
primary care centres where mental health service inte-
gration is planned is essential. The absence of NMS in
our sample may be due to the use of low doses of medi-
cations in most cases. The use of benzodiazepines and
ECT might have also contributed given these two treat-
ments have been considered as treatment options for
NMS [44, 50]. The long duration of catatonia is worth
of note. This is generally consistent with the service
utilization pattern of patients with severe mental disor-
ders in the country [51], which in turn is likely to be re-
lated to the limited availability of services [52]. However,
because most patients were treatment naïve at entry into
the study, treatment with antipsychotic medications is un-
likely to explain the long duration of catatonia.
Strengths and limitations
The main strength of our study is its novelty. There are
extremely few studies on the subject in low and middle
income countries despite the prevailing view that catato-
nia is common in these countries. Most of our partici-
pants were also first episode cases and less affected by
the chornicity of the illness and prior treatment. Some
of the motor manifestations, particularly in schizophre-
nia, may be markers of chronicity or medication side ef-
fects. Administration of a standard instrument prior to
initiation of treatment and prior to discharge is also an
important advantage to this study. To our knowledge
there are very few prospective studies of catatonia in the
world. Given this rarity of prospective studies, our study
has the potential to contribute to our knowledge about
catatonia. However, this is a relatively small study al-
though this has been one of the main problems of studies
on catatonia. In addition to the low prevalence of catato-
nia, challenges of recruiting patients with catatonia, diffi-
culty of data collection and challenges of communication
are likely reasons for small sample sizes in many studies of
catatonia. Our study sample was consecutive but instru-
ments were not systematically administered to all admit-
ted patients. Instead, patients identified with catatonia by
treating psychiatrists were referred to the research team.
Therefore, patients with non-classical catatonia symptoms
such as excitement could have been missed. It was diffi-
cult to obtain adequate description of the catatonic state
from our participants. Some of the possible explanations
include: the narrow window of opportunity to administer
the questionnaire, residual catatonic symptoms or symp-
toms of the underlying illness and the possible cognitive
effect of treatment modalities such as ECT [9, 11–13, 53].
Conclusions
Despite a good overall outcome, the incidence of life-
threatening complications in catatonia is not negligible.
This risk has to be taken into account in the context of
the current efforts to improve service coverage in Low
and Middle Income Countries (LAMICs). The study also
indicates an urgent need for developing evidence base
for the treatment of catatonia in low income countries
given the limitation of treatment options in these set-
tings. Treatments known to be effective, particularly lor-
azepam should be made available in Ethiopia. Our study
indicates that a study on catatonia is feasible. Further
systematic studies characterizing the nature of catatonia,
its etiology and treatment are essential.
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